Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Xenetic Biosciences Inc
Healthcare
P/NCAV
0.67x
Ticker
XBIO
Exchange
NASDAQ
Country
United States
Close
3.84 $
Mkt Cap
5.9M $
EV
-3.1M $
NCAV Burn Rate
30.2%
Current Ratio
11.84
Debt/Equity
0.0
EV/REV
-1.23x
EV/EBIT
0.7x
EV/FCF
0.8x
Dilution
52.4% p.A
Total Net Income
-131.9M $
Cheapness
86.0%
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company-s DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average